Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients

References

• Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J Am Med Assoc 1999;281:249–54
   PubMed Web of Science ®Google Scholar
• Christomanou H, Chabas A, Pampols T, Guardiola A. Activator protein deficient Gaucher’s disease. A second patient with the newly identified lipid storage disorder. Klin Wochenschr 1989;67:999–1003
   Google Scholar
• Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun 1965;18:221–5
   PubMed Web of Science ®Google Scholar
• Gaucher PCE. De l’epithélioma primitif de la rate, hypertrophie idiopathique de la rate sans leucémie [MD Thesis]. Faculté de Médicine de Paris, Paris, France; 1882
   Google Scholar
• Cox TM, Schofield JP. Gaucher’s disease: clinical features and natural history. Bailliere’s Clin Haematol 1997;10:657–89
   PubMed Web of Science ®Google Scholar
• Grabowski GA. Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1997;1:5–12
   PubMedGoogle Scholar
• Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151–6
   PubMed Web of Science ®Google Scholar
• Pinto R, Caseiro C, Lemos M, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004;12:87–92
   PubMed Web of Science ®Google Scholar
• Zimran A, Kay A, Gelbart T, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992;71: 337–53
   Google Scholar
• Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, et al. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis 2000;23:77–82
   Google Scholar
• Sack Jr GH. Clinical diversity in Gaucher’s disease. Johns Hopkins Med J 1980;146:166–70
   PubMedGoogle Scholar
• Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002;75 (Suppl 1):A2–12
   PubMedGoogle Scholar
• Kane PA, Meili-Vergani G, Williams R, Karani JB. Pseudotumours of hepatic imaging. Clin Radiol 1996;51:362–5
   PubMed Web of Science ®Google Scholar
• Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002;77:91–8
   PubMed Web of Science ®Google Scholar
• Lachmann RH, Wight DG, Lomas DJ, et al. Massive hepatic fibrosis in Gaucher’s disease: clinico-pathological and radiological features. Q J Med 2000;93:237–44
   Google Scholar
• de Fost M, vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006;36:53–8
   PubMed Web of Science ®Google Scholar
• Mariani G, Filocamo M, Giona F, et al. Severity of bone marrow involvement in patients with Gaucher’s disease evaluated by scintigraphy with99mTc-Sestamibi. J Nucl Med 2003;44: 1253–62
   PubMed Web of Science ®Google Scholar
• Itzchaki M, Lebel E, Dweck A, et al. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy. Acta Orthop Scand 2004;75:641–53
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Aggio MC, Andersson HC, et al.; International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004;41(Suppl 5):15–22
   Google Scholar
• Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine (Baltimore) 1985;64:310–22
   PubMed Web of Science ®Google Scholar
• Elstein D, Itzchaki M, Mankin HJ. Skeletal involvement in Gaucher’s disease. Bailliere’s Clin Haematol 1997;10:793–816
   PubMedGoogle Scholar
• Esplin JA, MCPherson EJ. Treatment of bone complications in patients with Gaucher disease. Gaucher Clin Perspectives 1994;2:7–11
   Google Scholar
• Bembi B, Ciana G, Mengel E, et al. Bone complications in children with Gaucher disease. Br J Radiol 2002;75(Suppl 1): A37–A44
   PubMedGoogle Scholar
• Brady RO. The sphingolipidoses. New Engl J Med 1966;275: 312–8
   PubMed Web of Science ®Google Scholar
• Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162:570–2
   Google Scholar
• Beutler E, Dale GL, Guinto DE, Kuhl W. Enzyme replacement therapy in Gaucher’s disease: preliminary clinical trial of a new enzyme preparation. Proc Natl Acad Sci USA 1977;74:4620–3
   PubMed Web of Science ®Google Scholar
• Brady RO, Pentchev PG, Gal AE, et al. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebros-idase in Gaucher’s disease. New Engl J Med 1974;291: 989–93
   PubMed Web of Science ®Google Scholar
• Sly WS, Kaplan A, Achord DT, et al. Receptor-mediated uptake of lysosomal enzymes. Prog Clin Biol Res 1978;23:547–51
   PubMedGoogle Scholar
• Furbish FS, Steer CJ, Krett NL, Barranger JA. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 1981;673:425–34
   PubMed Web of Science ®Google Scholar
• Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher’s disease. New Engl J Med 1991;324:1464–70
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33–9
   PubMed Web of Science ®Google Scholar
• Germain DP. Gaucher’s disease: a paradigm for interventional genetics. Clin Genet 2004;65:77–86
   PubMed Web of Science ®Google Scholar
• Futerman AH, Sussman JL, Horowitz M, et al. New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 2004;25:147–51
   PubMed Web of Science ®Google Scholar
• Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005;27: 1215–27
   Google Scholar
• Cox TM, Aerts JM, Andria G, et al.; Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003;26: 513–26
   Google Scholar
• European Medicines Agency. Summary of product characteristics. http://www.emea.eu.int/humandocs/Humans/EPAR/cerezyme/cerezyme.htm
   Google Scholar
• Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112–9
   PubMed Web of Science ®Google Scholar
• Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993;82: 408–16
   Google Scholar
• Goldblatt J, Szer J, Fletcher JM, et al. Enzyme replacement therapy for Gaucher disease in Australia. Int Med J 2005;35: 156–61
   Google Scholar
• Poll LW, Maas M, Terk MR, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 2002;75(Suppl 1):A25–A36
   PubMedGoogle Scholar
• Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995;96:629–37
   PubMed Web of Science ®Google Scholar
• Baldellou A, Andria G, Campbell PE, et al. Paediatric nonneuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004;163:67–75
   PubMed Web of Science ®Google Scholar
• Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41 (Suppl 5):4–14
   PubMedGoogle Scholar
• Andersson HC, Charrow J, Kaplan P, et al.; International Collaborative Gaucher Group, US Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005;7:105–10. Errata in: Genet Med 2005;7(6):460, Genet Med 2005;7(7):514
   Google Scholar
• Minchew JT, Dawson EG. The spine and Gaucher disease. Gaucher Clin Perspectives 1991;2:1–6
   Google Scholar
• Cormier C. Markers of bone metabolism. Curr Opin Rheumatol 1995;7:243–8
   PubMedGoogle Scholar
• Delmas PD, Eastell R, Garnero P, et al.; Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000;11(Suppl 6)S2–S17
   Google Scholar
• Seibel MJ, Woitge HW. Basic principles and clinical applications of biochemical markers of bone metabolism: biochemical and technical aspects. J Clin Densitom 1999;2:299–321
   PubMed Web of Science ®Google Scholar
• Bettica P, Taylor AK, Talbot J, et al. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab 1996;81:542–6
   PubMed Web of Science ®Google Scholar
• Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999;45:1359–68
   PubMed Web of Science ®Google Scholar
• Drexler HG, Gignac SM. Characterization and expression of tartrate-resistant acid phosphatase (TRAP) in hematopoietic cells. Leukemia 1994;8:359–68
   PubMed Web of Science ®Google Scholar
• Hayman AR, Macary P, Lehner PJ, Cox TM. Tartrate-resistant acid phosphatase (Acp 5): identification in diverse human tissues and dendritic cells. J Histochem Cytochem 2001;49: 675–84
   PubMed Web of Science ®Google Scholar
• Mankin HJ, Doppelt SH, Rosenberg AE, Barranger JA. In: Avioli LV, Krane SM, editors. Metabolic bone disease, 2nd ed. Philadelphia (PA): Saunders; 1990. p. 732–50
   Google Scholar
• Fiore CE, Barone R, Pennisi P, et al. Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease. J Bone Miner Metab 2002;20:34–8
   PubMed Web of Science ®Google Scholar
• Ciana G, Martini C, Leopaldi A, et al. Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 2003;72:185–9
   PubMed Web of Science ®Google Scholar
• Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in Type 1 Gaucher disease. J Bone Miner Res 1996;11:1801–7
   PubMed Web of Science ®Google Scholar
• Hermann G, Goldblatt J, Levy RN, et al. Gaucher’s disease type 1: assessment of bone involvement by CT and scintigraphy. Am J Roentgenol 1986;147:943–8
   PubMed Web of Science ®Google Scholar
• Drugan C, Jebeleanu G, Grigorescu-Sido P, et al. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2002;28: 13–20
   Google Scholar
• Ciana G, Addobbati R, Tamaro G, et al. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 2005;28:723–32
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Mankin H, Dambrosia JM, et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 2002;28:288–96
   PubMed Web of Science ®Google Scholar
• Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004;104:1253–7
   PubMed Web of Science ®Google Scholar
• van den Berg WB, Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I. Bailliere’s Best Pract Res Clin Rheumatol 1999;13: 577–97
   PubMed Web of Science ®Google Scholar
• Chikanza I, Fernandes L. Novel strategies for the treatment of osteoarthritis. Expert Opin Investig Drugs 2000;9:499–510
   Google Scholar
• Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1992;6: 285–95
   PubMed Web of Science ®Google Scholar
• Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999;13:1117–25
   PubMed Web of Science ®Google Scholar
• Allen MJ, Myer BJ, Khokher AM, et al. Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: increased release of interleukin-6 and interleukin-10. Q J Med 1997; 90:19–25
   Google Scholar
• Ishikawa H, Tsuyama N, Liu S, et al. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 2005;24:6328–32
   PubMed Web of Science ®Google Scholar
• Michelakakis H, Spanou C, Kondyli A, et al. Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta 1996;1317:219–22
   PubMed Web of Science ®Google Scholar
• Lichtenstein M, Zimran A, Horowitz M. Cytokine mRNA in Gaucher disease. Blood Cells Mol Dis 1997;23:395–401
   PubMedGoogle Scholar
• Moran MT, Schofield JP, Hayman AR, et al. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000;96:1969–78
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23–35
   PubMed Web of Science ®Google Scholar
• Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004;122:359–69
   PubMed Web of Science ®Google Scholar
• Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005;105:4569–72
   PubMed Web of Science ®Google Scholar
• Altarescu G, Phillips M, Foldes AJ, et al. The interleukin-6 promoter polymorphism in Gaucher disease: a new modifier gene? Q J Med 2003;96:575–8
   Google Scholar
• Altarescu G, Zimran A, Michelakakis H, Elstein D. TNF-alpha levels and TNF-alpha gene polymorphism in type I Gaucher disease. Cytokine 2005;31(2):149–52
   PubMed Web of Science ®Google Scholar
• Delaisse JM, Engsig MT, Everts V, et al. Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta 2000;291:223–34
   PubMed Web of Science ®Google Scholar
• Everts V, Hou WS, Rialland X, et al. Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif Tissue Int 2003;73:380–6
   PubMed Web of Science ®Google Scholar
• Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001;81:1319–28
   Google Scholar
• Simonaro CM, D’Angelo M, Haskins ME, Schuchman EH. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005;57:701–7
   PubMed Web of Science ®Google Scholar
• Pan C, Nelson MS, Reyes M, et al. Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells. Blood 2005;106:1956–64
   PubMed Web of Science ®Google Scholar
• Poll LW, Koch JA, Willers R, et al. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis 2002;28:209–20
   PubMed Web of Science ®Google Scholar
• Czartoryska B, Tylki-Szymanska A, Gorska D. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Clin Biochem 1998;31:417–20
   PubMed Web of Science ®Google Scholar
• Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, et al. Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 2003;278:40911–6
   Google Scholar
• Mankin HJ, Sims KB, Bove CM. Erlenmeyer flasking of a child’s bones: a diagnostic puzzle. Am J Orthop 2005;34:393–5
   Google Scholar
• Maas M, Poll LW, Terk MR. Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol 2002;75(Suppl 1): A13–A24
   Google Scholar
• Tran HA. Erlenmeyer flask. J Clin Endocrinol Metab 2004;89:4827–8
   PubMed Web of Science ®Google Scholar
• Vogler 3rd JB, Murphy WA. Bone marrow imaging. Radiology 1988;168:679–93
   Google Scholar
• Foster K, Chapman S, Johnson K. MRI of the marrow in the paediatric skeleton. Clin Radiol 2004;59:651–73
   Google Scholar
• Babyn PS, Ranson M, McCarville ME. Normal bone marrow: signal characteristics and fatty conversion. Magn Reson Imaging Clin North Am 1998;6:473–95
   Google Scholar
• Rosenthal DI, Scott JA, Barranger J, et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am 1986;68:802–8
   PubMedGoogle Scholar
• Poll LW, Koch JA, vom Dahl S, et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol 2001;9:496–503
   Google Scholar
• Terk MR, Dardashti S, Liebman HA. Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol 2000;29: 563–71
   Google Scholar
• Vlieger EJ, Maas M, Akkerman EM, et al. Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease. J Comput Assisted Tomogr 2002;26:843–8
   PubMed Web of Science ®Google Scholar
• Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging – initial experience. Radiology 2003;229: 554–61
   PubMed Web of Science ®Google Scholar
• Miller SP, Zirzow GC, Doppelt SH, et al. Analysis of the lipids of normal and Gaucher bone marrow. J Lab Clin Med 1996;127:353–8
   PubMedGoogle Scholar
• Hollak C, Maas M, Akkerman E, et al. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 2001;27:1005–12
   PubMed Web of Science ®Google Scholar
• Maas M, Hollak CE, Akkerman EM, et al. Quantification of skeletal involvement in adults with type I Gaucher’s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am J Roentgenol 2002;179:961–5
   PubMed Web of Science ®Google Scholar
• Johnson LA, Hoppel BE, Gerard EL, et al. Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 1992;182:451–5
   PubMed Web of Science ®Google Scholar
• Ansari SM, Begum T, Siddique AB. Usefulness of bone mineral density measurement in menopausal woman: a study of 217 post menopausal women. Bangladesh Med Res Counc Bull 2004;30: 25–30
   Google Scholar
• Lebel E, Dweck A, Foldes AJ, et al. Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 2004;22:597–601
   PubMed Web of Science ®Google Scholar
• Tran SD, Terk MR, Colletti PM. Proton MR spectroscopy of bone marrow: precision and reliability. Am J Roentgenol 2000;174(Suppl:60)
   Google Scholar
• Pastores GM, Hermann G, Norton KI, et al. Regression of skeletal changes in type 1 Gaucher disease with enzyme replacement therapy. Skeletal Radiol 1996;25:485–8
   PubMed Web of Science ®Google Scholar
• Lorberboym M, Pastores GM, Kim CK, et al. Scintigraphic monitoring of reticuloendothelial system in patients with type 1 Gaucher disease on enzyme replacement therapy. J Nucl Med 1997;38:890–5
   PubMed Web of Science ®Google Scholar
• Lorberboym M, Vallabhajosula S, Lipszyc H, Pastores GM. Potential of 99mTc-LDL scintigraphy suggested for monitoring the efficacy of ERT. Clin Genet 1997;52:7–11
   PubMedGoogle Scholar
• Rosenthal DI, Barton NW, McKusick KA, et al. Quantitative imaging of Gaucher disease. Radiology 1992;185:841–5
   PubMed Web of Science ®Google Scholar
• Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher’s disease. Lancet 1996;348:1555–9
   Google Scholar
• Mariani G, Molea N, La Civita L, et al. Scintigraphic findings on 99mTc-MDP, 99mTc-Sestamibi and 99mTc-HMPAO images in Gaucher disease. Eur J Nucl Med 1996;23:466–70
   PubMedGoogle Scholar
• Blocklet D, Abramowicz M, Scoutens A. Bone, bone marrow and MIBI scintigraphic findings in Gaucher’s disease ‘bone crisis’. Clin Nucl Med 2001;26:865–9
   Google Scholar
• Aharoni D, Krausz Y, Elstein D, et al. Tc-99m Sestamibi bone marrow scintigraphy in Gaucher disease. Clin Nucl Med 2002;27:503–9
   PubMed Web of Science ®Google Scholar
• Mariani G, Filocamo M, Giona F, et al. Severity of bone marrow involvement in patients with Gaucher’s disease evaluated by scintigraphy with99mTc-Sestamibi. J Nucl Med 2003;44:253–1262
   Google Scholar
• Data presented at: ‘Gaucher disease: focus on skeletal complications’, Gaslini Children’s Hospital, Genoa, Italy, February 2005
   Google Scholar
• Zimran A, Kay A, Gelbart T, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992;71: 337–53
   Google Scholar
• Erba G, Giona F, Minichilli F, et al. Assessment of the long-term efficacy of enzyme replacement therapy by 99mTc-Sestamibi bone marrow scintigraphy in patients with Gaucher disease. J Nucl Med 2004;45(Suppl):79p [abstract]
   Google Scholar
• Fischman SL, Elstein D, Sgan-Cohen H, et al. Dental profile of patients with Gaucher disease.BMC Oral Health. 2003;3:4
   Google Scholar
• Niederau C, Rolfs A, vom Dahl S, et al. Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000. Med Klin (Munich) 2001; 96:32–9
   Google Scholar
• Manz M, Riessen R, Poll L, et al. High-grade lymphoma mimicking bone crisis in Gaucher’s disease. Br J Haematol 2001;113:191–3
   PubMed Web of Science ®Google Scholar
• vom Dahl S, Poll LW, Haussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 2001;113(4):1084–7
   Google Scholar
• Toth J, Erdos M, Marodi L. Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur J Haematol 2003;70: 125–8
   Google Scholar
• Migita M, Fukunaga Y, Ueda T, et al. Progression of bone disease without deterioration of hematological parameters in a child with Gaucher disease during low-dose glucocerebrosidase therapy. Nippon Ika Daigaku Zasshi 1994;61:633–7
   PubMedGoogle Scholar
• Ueda T, Fukunaga Y, Migita M, et al. Improvement of bone disease with increased dose of glucocerebrosidase in a Gaucher disease patient who had a bone lesion presenting during low-dose enzyme replacement therapy. Acta Paediatr Jpn 1996;38:260–4
   PubMedGoogle Scholar
• De Fost M, Hollak CE, Groener A, et al. Superior effects of high-dose enzyme supplementation therapy in type I Gaucher disease on bone marrow involvement and chitotriosidase levels: a two center retrospective analysis. Blood 2006 March 9; [epub ahead of print]
   Google Scholar
• Figueroa ML, Rosenbloom BE, Kay AC, et al. A less costly regimen of alglucerase to treat Gaucher’s disease. New Engl J Med 1992;327:1632–6
   PubMed Web of Science ®Google Scholar
• Elstein D, Abrahamov A, Itzchaki M, Zimran A. Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis 1998;24:303–5 [discussion 306–8]
   Google Scholar
• Beutler E. Treatment regimens in Gaucher’s disease. Lancet 1995;346:581–2
   PubMed Web of Science ®Google Scholar
• Kenet G, Hayek S, Mor M, et al. The 1226G (N370S) Gaucher mutation among patients with Legg-Calve-Perthes disease. Blood Cells Mol Dis 2003;31:72–4
   PubMed Web of Science ®Google Scholar
• Cox TM. Gaucher’s disease – an exemplary monogenic disorder. Q J Med 2001;94:399–402
   Google Scholar
• Maas M, Goldblatt J, Robertson P. Skeletal monitoring and preliminary results. Data presented at the Australian Gaucher Treaters’ Meeting, Melbourne, Australia, August 2005
   Google Scholar